Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | GUCY1B2 | O75343 | 9/20 | 0.37 |
| ▸ | GUCY1A2 | P33402 | 9/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585517 | 0.91 | MAPT (0.48) | PTGER1MAPTSMN1; SMN2GCGR | |
| SCHEMBL5585777 | 0.91 | PTGER1 (0.49) | PTGER1MRGPRX4 | |
| SCHEMBL5585518 | 0.91 | PTGER1 (0.42) | PTGER1MAPTSMN1; SMN2RXRARXRB | |
| SCHEMBL5585563 | 0.85 | PTGER1 (0.40) | PTGER1RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL5585639 | 0.84 | PTGER1 (0.50) | PTGER1 | |
| SCHEMBL5585513 | 0.84 | NPSR1 (0.41) | MAPTSMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL5585434 | 0.83 | GCGR (0.44) | PTGER1RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL5585429 | 0.83 | PTGER1 (0.52) | PTGER1 | |
| SCHEMBL5585453 | 0.83 | MRGPRX4 (0.40) | PTGER1SMN1; SMN2MRGPRX4GCGR | |
| SCHEMBL5585646 | 0.81 | PTGER1 (0.48) | PTGER1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | PTGER1 3758/4885GUCY1B2 1457/4885GUCY1A2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.